1. Home
  2. NRO vs MDWD Comparison

NRO vs MDWD Comparison

Compare NRO & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neuberger Berman Real Estate Securities Income Fund Inc.

NRO

Neuberger Berman Real Estate Securities Income Fund Inc.

HOLD

Current Price

$2.93

Market Cap

199.6M

Sector

Finance

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$18.88

Market Cap

230.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRO
MDWD
Founded
2003
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Finance/Investors Services
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
199.6M
230.7M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
NRO
MDWD
Price
$2.93
$18.88
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$37.50
AVG Volume (30 Days)
239.4K
96.8K
Earning Date
01-01-0001
11-20-2025
Dividend Yield
11.41%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$20,932,000.00
Revenue This Year
N/A
$15.89
Revenue Next Year
N/A
$25.33
P/E Ratio
N/A
N/A
Revenue Growth
N/A
6.15
52 Week Low
$2.51
$14.14
52 Week High
$3.45
$22.51

Technical Indicators

Market Signals
Indicator
NRO
MDWD
Relative Strength Index (RSI) 30.78 57.36
Support Level $2.96 $18.71
Resistance Level $3.06 $19.63
Average True Range (ATR) 0.03 0.67
MACD -0.00 0.16
Stochastic Oscillator 0.94 70.95

Price Performance

Historical Comparison
NRO
MDWD

About NRO Neuberger Berman Real Estate Securities Income Fund Inc.

NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: